News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Invasive Breast Carcinoma → cancer profile · × Clear filters
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
The Journal of Clinical Oncology has published HER2CLIMB-05, a randomised phase 3 trial evaluating the addition of tucatinib to the standard first-line backbone of trastuzumab and pertuzumab as maintenance therapy in HER2-positive metastatic breast cancer. Tucatinib is a highly selective oral HER2-targeted tyrosine kinase inhibitor, so far approved for later-line disease on the basis of the HER2CL…
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
The Journal of Clinical Oncology has published full results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib, a pan-class I PI3K/mTOR dual inhibitor, combined with fulvestrant with or without palbociclib in patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring wild-type PIK3CA. This trial addresses a critical unmet need, as current PI3K-targeted agents suc…
2026 Society of Surgical Oncology Annual Meeting
At the 2026 Society of Surgical Oncology Annual Meeting, Martin Heidinger presented results from a preplanned analysis of the TAXIS/OPBC-03 phase 3 trial, which evaluated tailored axillary surgery (TAS) as an alternative to standard axillary lymph node dissection (ALND) in patients with node-positive breast cancer. The trial investigated whether reducing axillary tumour burden through a less radic…
In what clinical settings are the MASAI trial results applicable?
Nature Reviews Clinical Oncology has published a commentary analyzing the clinical significance of the MASAI (Mammography Screening with Artificial Intelligence) trial, which is believed to be the first randomized controlled trial of AI-supported mammography interpretation to evaluate interval cancer rates as an endpoint. The Swedish trial demonstrated that using artificial intelligence to triage …
Datopotamab deruxtecan extends overall survival in first-line metastatic TNBC when immunotherapy is not an option: 23.7 versus 18.7 months (TROPION-Breast02)
In the phase 3 TROPION-Breast02 trial, datopotamab deruxtecan — a TROP2-directed antibody-drug conjugate — extended median overall survival to 23.7 months versus 18.7 months with the investigator's choice of chemotherapy (HR 0.79; 95% CI 0.64-0.98; p=0.0291), with median progression-free survival of 10.8 versus 5.6 months (HR 0.57; 95% CI 0.47-0.69; p<0.0001). The trial enrolled first-line locally…